TWD 74.3
(-0.93%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 802.78 Million TWD | 3007.95% |
2022 | -27.68 Million TWD | 87.72% |
2021 | -225.4 Million TWD | 13.14% |
2020 | -264 Million TWD | -40.51% |
2019 | -184.68 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 112.08 Million TWD | -34.21% |
2024 Q1 | 169.14 Million TWD | -2.2% |
2023 Q1 | 245.29 Million TWD | 289.3% |
2023 FY | - TWD | 3007.95% |
2023 Q4 | 173.67 Million TWD | 21.74% |
2023 Q3 | 142.66 Million TWD | -41.41% |
2023 Q2 | 243.51 Million TWD | -0.73% |
2022 FY | - TWD | 87.72% |
2022 Q4 | 63 Million TWD | 0.0% |
2021 FY | - TWD | 13.14% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | -292.0% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | -247.384% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 1038.918% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 47.337% |
Synmosa Biopharma Corporation | 1 Billion TWD | 20.417% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | -37.714% |
Center Laboratories, Inc. | -175.17 Million TWD | 558.289% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -2485.622% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | -365.665% |
InnoPharmax Inc. | -62.12 Million TWD | 1392.312% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | -533.72% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 2833.44% |
DV Biomed Co., Ltd. | 407.64 Million TWD | -96.935% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 188.009% |
UniPharma Co., Ltd. | -16.25 Million TWD | 5038.993% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | -511.365% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | -103.484% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | -251.597% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 2156.628% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -6515.443% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -708.036% |